Olivier Dirat
Overview
Explore the profile of Olivier Dirat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien Laramy M, Foley D, Pak R, Lewis J, McKinney E, Egan P, et al.
Nat Nanotechnol
. 2025 Jan;
PMID: 39821140
Lipid nanoparticles (LNPs) for nucleic acid delivery often use novel lipids as functional excipients to modulate the biodistribution, pharmacokinetics, pharmacodynamics and efficacy of the nucleic acid. Novel excipients used in...
2.
Bercu J, Dirat O, Dobo K, Jolly R, Kenyon M, Harvey J, et al.
Regul Toxicol Pharmacol
. 2024 Sep;
154:105704.
PMID: 39326488
The carcinogenicity potency categorization approach (CPCA) derived and harmonized by Health Authorities was a significant milestone, as it defined molecular properties that allowed for the rapid evaluation of the chemical...
3.
Miesle J, Osei-Yeboah F, Pauli-Bruns A, Chen B, Manceva S, Wade J, et al.
Pharm Res
. 2024 Sep;
41(9):1775-1786.
PMID: 39231907
Purpose: The concept of a Design Space (DSp) was introduced in ICH Q8 as a tool within the quality-by-design (QbD) approach to pharmaceutical development with the intent of being globally...
4.
Yu S, McWilliams J, Dirat O, Dobo K, Kalgutkar A, Kenyon M, et al.
Chem Res Toxicol
. 2024 Jul;
37(8):1382-1393.
PMID: 39075630
Understanding the potential carcinogenic potency of nitrosamines is necessary to setting acceptable intake limits. Nitrosamines and the components that can form them are commonly present in food, water, cosmetics, and...
5.
Schenck L, Patel P, Sood R, Bonaga L, Capella P, Dirat O, et al.
J Pharm Sci
. 2023 Jan;
112(8):2069-2078.
PMID: 36638959
These proceedings contain presentation summaries and discussion highlights from the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) Workshop on Co-processed API, held on July 13...
6.
Dobo K, Kenyon M, Dirat O, Engel M, Fleetwood A, Martin M, et al.
Chem Res Toxicol
. 2022 Feb;
35(3):475-489.
PMID: 35212515
The potential for -nitrosamine impurities in pharmaceutical products presents a challenge for the quality management of medicinal products. -Nitrosamines are considered cohort-of-concern compounds due to the potent carcinogenicity of many...
7.
Elliott J, Carlson E, Chicchi G, Dirat O, Dominguez M, Gerhard U, et al.
Bioorg Med Chem Lett
. 2006 Apr;
16(11):2929-32.
PMID: 16574413
A new class of high affinity hNK1R antagonists based on seven-membered ring cores has been identified. This series, with relatively simple, compact structures, includes compounds with high affinity, good selectivity,...
8.
Hollingworth G, Carlson E, Castro J, Chicchi G, Clark N, Cooper L, et al.
Bioorg Med Chem Lett
. 2005 Dec;
16(5):1197-201.
PMID: 16384700
A series of 4,4-disubstituted cyclohexylamine NK(1) antagonists containing a lactam ring is described. The compounds are brain penetrant and activity is demonstrated in a ferret emesis model.
9.
Trost B, Dirat O, Gunzner J
Angew Chem Int Ed Engl
. 2002 Dec;
41(5):841-3.
PMID: 12491354
No abstract available.
10.
Trost B, Gunzner J, Dirat O, Rhee Y
J Am Chem Soc
. 2002 Aug;
124(35):10396-415.
PMID: 12197742
The total synthesis of the novel antitumor agent callipeltoside A, as well as several analogues, is accomplished and allows assignment of the stereochemistry not previously established. A convergent strategy is...